Larotrectinib can be effective in patients with ETV6-NTRK3–positive B-cell lymphoblastic leukemia, inducing prolonged molecular remission. Single-agent tyrosine kinase inhibitor treatment could be a valuable treatment option in subgroups of kinase fusion–positive ALL patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880891 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2019000700 | DOI Listing |
Publication Analysis
Top Keywords
lymphoblastic leukemia
8
larotrectinib trk
4
trk fusion-positive
4
fusion-positive pediatric
4
pediatric b-cell
4
b-cell acute
4
acute lymphoblastic
4
leukemia larotrectinib
4
larotrectinib effective
4
effective patients
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!